AED evaluated
|
Sodium Valproate
|
Gabapentin
|
2
nd
AED
|
PB (11 dogs)
|
Primidone (6 dogs)
|
PB (24 dogs)
|
-
|
PB (17 dogs)
|
PB (11 dogs)
|
3
rd
AED
|
Phenytoin (11 dogs)
|
-
|
-
|
-
|
PBr (16 dogs)
|
PBr (11 dogs)
|
4
th
AED
|
-
|
-
|
-
|
-
|
-
|
-
|
No of dogs
|
11
|
6
|
24
|
16
|
17
|
11
|
Period of treatment (months)
|
mean, 4.9; range, 1-8
| |
4
|
3
|
Dose of AED(s) (mg/kg)
|
range 25–40 PO SID (PB and Phenytoin doses were not reported)
|
range, 30–45 PO SID; Primidone: NA
|
range, 30–110 PO SID; PB: NA
|
range, 25–105 PO SID
|
median, 35; range, 32–40 PO SID; PB: median, 8; range, 6–12 PO SID; PBr: median, 24; range, 14–30 PO SID
|
mean, 10.9; 9.3-13.6 PO TID; PB and PBr: NA but were within normal reference values based on the serum levels
|
Pre-treatment SF (seizures/month)
|
mean, 2.7 (period was not recorded)
|
median, 2; range, 1–4 (recorded over a period of median 1.5 years)
|
median, 6; 2–140 (recorded over a period of 3 m)
|
Post-treatment SF (seizures/month)
|
NA
|
median, 1; range, 0.5-3
|
median, 2; range, 0-4
|
No of dogs that were failures
|
4/11 (36%)
|
3/6 (50%)
|
8/24 (34%)
|
9/16 (56%)
|
6/17 (35%)
|
1/11 (9%)
|
No of dogs with >0% - <50% reduction in SF
|
1/11 (9%)
|
2/6 (33%)
|
2/24 (8%)
|
7/16 (44%)
|
1/17 (6%)
|
4/11 (36%)
|
No of dogs with ≥50% - <100% reduction in SF
|
6/11 (55%)
|
1/6 (17%)
|
14/24 (58%)
|
7/16 (44%)
|
7/17 (42%)
|
6/11 (55%)
|
No of dogs with 100% reduction in SF
|
-
|
-
|
-
|
-
|
3/17 (17%)
|
-
|
No of dogs with >30% reduction in SF
|
6/11 (55%)
|
1/6 (17%)
|
14/24 (58%)
|
7/16 (44%)
|
10/17 (59%)
|
9/11 (82%)
|
95% CI successfully treated cases
|
30% - 84%
|
−13% - 47%
|
38% - 78%
|
20% - 68%
|
36% - 82%
|
26% - 84%
|
Overall evidence for/against recommending the use of an AED
|
Insufficient evidence for recommending the use of sodium valproate either as a monotherapy or an adjunct AED.
|
Insufficient evidence for recommending the use of gabapentin as an adjunct AED.
|